Romiplostim

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 860 publications

Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia.

Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia.

Journal: The New England journal of medicine

Published: June 03, 2026

Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia. Reply.

Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia. Reply.

Journal: The New England journal of medicine

Published: June 03, 2026

Correction: Romiplostim in Aplastic Anemia: A Single-Center Retrospective Study.

Correction: Romiplostim in Aplastic Anemia: A Single-Center Retrospective Study.

Journal: Cureus

Published: May 22, 2026

Neonatal-Onset Refractory Thrombocytopenia and Anemia Associated With a Homozygous In-Frame NFE2 Duplication.

Neonatal-Onset Refractory Thrombocytopenia and Anemia Associated With a Homozygous In-Frame NFE2 Duplication.

Journal: The American journal of case reports

Published: May 19, 2026

Cerebral Venous Thrombosis Involving the Vein of Labbé and Left Sigmoid Sinus in a Patient With Immune Thrombocytopenia Treated With Romiplostim: A Case Report and Literature Review.

Cerebral Venous Thrombosis Involving the Vein of Labbé and Left Sigmoid Sinus in a Patient With Immune Thrombocytopenia Treated With Romiplostim: A Case Report and Literature Review.

Journal: Cureus

Published: April 23, 2026

Romiplostim Use in Pancytopenia Secondary to Azathioprine Overdose in a Dog.

Romiplostim Use in Pancytopenia Secondary to Azathioprine Overdose in a Dog.

Journal: Journal of the American Animal Hospital Association

Published: April 21, 2026

Single-cell transcriptome deciphers key targets of thrombopoietin receptor agonists and immune microenvironment characteristics of immune thrombocytopenia.

Single-cell transcriptome deciphers key targets of thrombopoietin receptor agonists and immune microenvironment characteristics of immune thrombocytopenia.

Journal: Platelets

Published: April 01, 2026

Successful combination therapy with fostamatinib and romiplostim in refractory immune thrombocytopenia 27 years after onset

Successful combination therapy with fostamatinib and romiplostim in refractory immune thrombocytopenia 27 years after onset

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: March 29, 2026

Long-term safety and effectiveness of romiplostim in patients with refractory aplastic anemia: a nationwide, all-case, post-marketing surveillance study in Japan.

Long-term safety and effectiveness of romiplostim in patients with refractory aplastic anemia: a nationwide, all-case, post-marketing surveillance study in Japan.

Journal: Annals of hematology

Published: March 25, 2026

Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management.

Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management.

Journal: Expert opinion on pharmacotherapy

Published: March 24, 2026

Efficacy and safety of romiplostim N01 for refractory aplastic anemia: a retrospective single-center study

Efficacy and safety of romiplostim N01 for refractory aplastic anemia: a retrospective single-center study

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: March 16, 2026

Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia.

Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia.

Journal: The New England journal of medicine

Published: March 11, 2026

Showing 1-12 of 860

Last Updated: 06/30/2026